Dr. Kishor Gopaldas Bhatia Ph.D. Net Worth

Dr. Kishor Gopaldas Bhatia Ph.D. biography

Dr. Kishor Gopaldas Bhatia Ph.D. is the Chief Scientific Officer & Scientific Consultant at Lantern Pharma.

What is the salary of Dr D?

As the Chief Scientific Officer & Scientific Consultant of Lantern Pharma, the total compensation of Dr D at Lantern Pharma is 92,886$. There are 2 executives at Lantern Pharma getting paid more, with Panna Sharma having the highest compensation of 750,492$.

How old is Dr D?

Dr D is 66, he's been the Chief Scientific Officer & Scientific Consultant of Lantern Pharma since . There are no older and 2 younger executives at Lantern Pharma.

What's Dr D's mailing address?

Kishor's mailing address filed with the SEC is 1920 MCKINNEY AVENUE, 7TH FLOOR, , DALLAS, TX, 75201.

Insiders trading at Lantern Pharma

Over the last 4 years, insiders at Lantern Pharma have traded over 6,373,290$ worth of Lantern Pharma stock and bought 10,000 units worth 150,000$ . The most active insiders traders include Aaron G.L.Bios Fund I, Lpbi...、Leslie W.Cavu Management, L...、Maria Luisa Maccecchini. On average, Lantern Pharma executives and independent directors trade stock every 111 days with the average trade being worth of 423,325$. The most recent stock trade was executed by Leslie W.Cavu Management, L... on 23 May 2024, trading 30,000 units of LTRN stock currently worth 189,000$.

What does Lantern Pharma do?

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Lantern Pharma executives and stock owners

Lantern Pharma executives and other stock owners filed with the SEC include:

• Panna Sharma,
  Pres, CEO & Director
• David R. Margrave,
  CFO & Sec.
• Dr. Kishor Gopaldas Bhatia Ph.D.,
  Chief Scientific Officer & Scientific Consultant
• Nicole Leber,
  Fin. & Admin. Coordinator
• Dr. Peter L. Nara D.V.M., M.S., Ph.D.,
  Co-Founder & Advisor
• Park & Golf Ventures Ii, Ll...,
  
• Leslie W.Bios Equity Partne...,
  
• David S. Silberstein,
  Director
• Leslie W.Bp Directors, Lp B...,
  
• Aaron G.L.Bios Fund I, Lpbi...,
  
• Park & Golf Ventures Ii, Ll...,
  
• Arunkumar Asaithambi,
  
• Kishor G. Bhatia,
  Chief Scientific Officer
• Franklyn G Prendergast,
  Director
• D Jeffrey Keyser,
  Director
• Leslie W.Cavu Management, L...,
  
• David R. Margrave,
  Chief Financial Officer
• Panna Sharma,
  President and CEO
• Maria Luisa Maccecchini,
  Director